Replacement therapy in adults, children and adolescents (0-18 years) in:
- Primary immunodeficiency syndromes with impaired antibody production (see section 4.4),
- Hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic leukaemia (CLL), in whom prophylactic antibiotics have failed or are contra-indicated,
- Hypogammaglobulinaemia and recurrent infections in multiple myeloma (MM) patients,
- Hypogammaglobulinaemia in patients pre- and post-allogeneic haematopoietic stem cell transplantation (HSCT).
Hizentra is available in the following presentations:
- 1g in 5ml vial
- 2g in 10ml vial
- 4g in 20ml vial
For details on Hizentra at Home, our homecare services programme please click here.
Please visit our Privigen page for information on our Solution for Infusion, Human Normal Immunoglobulin.
Method of Sale: POM
License Number: EU/1/11/687/001, EU/1/11/687/004 & EU/1/11/687/010
MAH Holder: CSL Behring GmbH
Hizentra is distributed in Ireland by Fannin Ltd. in partnership with CSL Behring. (This link will take you to a non-Fannin Ltd. website. Fannin Ltd. does not recommend, endorse or accept liability for sites controlled by third-parties.)
Date of Preparation: October 2017